Opus Genetics announces first participant dosed in phase 1/2 trial of OPGx-RDH12 gene therapy
IRD•Opus Genetics said the first participant has been dosed in a phase 1/2 clinical trial of its OPGx-RDH12 gene therapy for rare inherited childhood blindness.
1. Trial begins
Opus Genetics announced that the first participant has been dosed in a phase 1/2 clinical trial of OPGx-RDH12 gene therapy for rare inherited childhood blindness.




